/ introducing
BrainStorm Therapeutics
Accelerating and de-risking the discovery of breakthrough medicines for complex neurological disorders.
/About Us
Transforming Neuroscience Drug Discovery and Development.
Utilizing patient biology, biomarker-based screening, and advanced data analytics to de-risk clinical translation.
Innovative approach
“Human-first” patient-derived brain organoid platform bridging the translational valley of death.
A Proprietary Platform
Leveraging human patient iPSC-derived models of brain disease and the computational tools of deep learning and network medicine to identify therapeutic candidates that halt, prevent, or reverse synaptic network dysfunction and
neurodegeneration.
Clinically Translatable Screening Endpoints
Identify, validate, and de-risk targets and screening hits across multiple disease-relevant endpoints.
Human Powered CNS Drug Discovery
Patient-inspired, ML/AI-powered.
/The Dilemma
There are no approved disease-modifying therapies for any neurodegenerative disorder
Lack of animal and cell culture models that accurately predict human efficacy.
Underlying heterogeneity of disease processes arising from a combination of genetic, environmental, and lifestyle factors.
Unlikely that a single drug engaging one target will be effective for substantial segments of the patient population.
Limited understanding of the impact of target biology on the complex network of intracellular and intercellular disease processes.
Dive into our
Revolutionary
technologies
Our Science
Patient-derived brain organoids are a powerful platform for CNS drug discovery.
Brain Organoids
Living, self-organized 3D structures derived from human iPSCs that mimic human brain tissue and exhibit highly synchronized and spontaneous synaptic network activity.
Biomarker-based Screening Endpoints
Capture robust and reproducible clinically translatable disease phenotypes that are amenable to multiple screening applications and high-content imaging.
De-risking Clinical Translation
Accelerate the generation of human efficacy and safety data, early in the R&D process, resulting in safer and more effective clinical candidates, enhancing clinical translation.
FDA Modernization Act 2
Recognizes that human brain organoids provide a more accurate and reliable evaluation of drug efficacy and safety reducing the reliance on animal work.
